GlaxoSmithKline Shares Fall on Vaccine Pipeline Concerns

GlaxoSmithKline's shares experienced a significant decline on October 28, 2026, as concerns about the company's vaccine pipeline and looming patent losses overshadowed positive quarterly results. The pharmaceutical firm reported third-quarter sales and profits that exceeded expectations, largely due to a 15 percent increase in demand for its specialized HIV and respiratory medications.

Despite the strong performance in these areas, investors reacted negatively to a 2 percent drop in vaccine sales and an increase in restructuring costs totaling £328 million. The share price fell as much as 5 percent, erasing its gains for the year. This downturn occurred as the company navigates a strategic overhaul led by Chief Executive Luke Miels, who assumed the role at the beginning of 2026. Miels is focused on developing a robust pipeline of new drugs to counter the impact of patent expirations on its HIV medication and on driving growth through cost-cutting measures initiated in July.

Analysts noted that the lack of major pipeline updates in the recent announcement left investors seeking clearer signs of future growth. "With no major pipeline updates just now, Miels will be hoping next year becomes one where the restructuring of the business begins to show in trial results," said Sheena Berry, an analyst at Quilter Cheviot.

While the company anticipates that new drug approvals will bolster future sales, it projected full-year earnings growth to be at the lower end of its previously guided range of 7 percent to 9 percent. Furthermore, research and development spending is expected to increase at a faster rate than sales.

Dan Coatsworth, head of markets at AJ Bell, commented on the situation, stating, "Miels has made progress and is continuing to bring down costs throughout the business. However, the latest update is a reminder he still has plenty of work to do."